Is there genetic susceptibility for atypical femoral fractures?

Injury. 2024 Feb;55(2):111312. doi: 10.1016/j.injury.2024.111312. Epub 2024 Jan 2.

Abstract

The mechanisms underlying AFF remain unclear, with hypotheses including bone turnover suppression and morphological variation. Recent studies have suggested a potential genetic susceptibility to AFF. A scoping review was conducted using PubMed to identify studies published since 2016. Twenty-one studies were identified, focusing on histological and genetic analysis of AFF patients and Bisphosphonates users. Biopsies and imaging modalities were used to assess histological and morphometric parameters, while genetic sequencing was performed to identify variants in target genes. Genetic studies identified variants in geranylgeranyl diphosphate synthase 1 (GGPS1) and CYP1A1 genes, which play roles in osteoclast function and drug metabolism, respectively. Functional analysis revealed reduced enzymatic activity in mutant variants of these genes, which could be further inhibited by BP use. Other genes, such as ATRAID, ALPL, and COL1A2, were also associated with AFF. Histomorphometric studies supported the hypothesis of bone turnover suppression in AFF, with alterations in tissue mechanical properties and microarchitecture observed, particularly in cortical bone. The findings suggest a potential genetic susceptibility to AFF, with variants in GGPS1 and CYP1A1 genes affecting osteoblast and osteoclast function. Bone turnover suppression and altered tissue properties contribute to the pathogenesis of AFF.

Keywords: Atypical femoral fractures; Bisphosphonates; Genetics; Histology; Morphology; Osteoporosis.

Publication types

  • Review
  • Editorial

MeSH terms

  • Bone Density Conservation Agents*
  • Bone and Bones / pathology
  • Cytochrome P-450 CYP1A1 / genetics
  • Diphosphonates
  • Femoral Fractures* / diagnostic imaging
  • Femoral Fractures* / genetics
  • Femoral Fractures* / pathology
  • Genetic Predisposition to Disease
  • Humans

Substances

  • Cytochrome P-450 CYP1A1
  • Diphosphonates
  • Bone Density Conservation Agents